Elanco Animal Health

One-line summary: US animal-health company (NYSE: ELAN) that won FDA emergency authorization for a livestock New World screwworm treatment in April 2026 — before the US outbreak was confirmed in June — making it the cleanest, and highest-beta, expression of the screwworm chain.

What it is

Elanco is an animal-health company spun out of Eli Lilly, with livestock and companion-animal franchises. It carries meaningfully more balance-sheet leverage than zoetis.

Why it matters to stock-market

• Regulatory pre-positioning is the whole edge. From 2026-07-10-autoresearch-screwworm-outbreak-cattle-herd-squeeze-beneficiaries: "Elanco (ELAN) won FDA emergency authorization for a livestock screwworm treatment in April 2026 — before the US outbreak was detected — plus an EUA for Credelio CAT in cats. Pre-positioned regulatory approval on an outbreak that then arrives is the cleanest version of this trade."
• Same unquantified caveat as zoetis: neither company's screwworm revenue exposure is sized anywhere in this wiki.
• Higher beta, weaker balance sheet. ELAN is the leveraged expression; ZTS the quality one.

Related

• screwworm-herd-rebuild-deferral-to-animal-health-rerate
• zoetis
• cattle-cycle-beef-supply-squeeze